Metabolic syndrome is a serious health condition that affects about 23% of adults in the United States, putting them at higher risk of cardiovascular disease, diabetes mellitus, stroke, and diseases related to buildup of fatty plaque in artery walls.
Diabetes mellitus is a group of metabolic diseases that increase the risk of microvascular and macrovascular complications.
Teprotumumab, an investigational drug, may slow progression of ophthalmopathy in patients with moderate to severe thyroid eye disease.
Excerpted from BCSC 2020-2021 series: Section 1 - Update on General Medicine. For more information and to purchase the entire series, please visit https://www.aao.org/bcsc.